A Study of ASA404 or Placebo in Combination With Docetaxel in Second-line Treatment for (Stage IIIb/IV) Non-small Cell Lung Cancer
The purpose of this study is to determine if adding ASA404 to docetaxel chemotherapy makes the cancer treatment more effective in patients with locally advanced or metastatic non-small cell lung cancer
Non-Small Cell Lung Cancer
DRUG: ASA404|DRUG: Placebo|DRUG: docetaxel
Overall survival, Every 6 weeks from study treatment discontinuation until death or loss to follow-up
Progression free survival, Every 6 weeks from study treatment discontinuation until documented PD, death or loss to follow-up|Overall response rate, Every 42 days (=/- 7 days) from date of randomization until PD|Quality of life, At every odd cycle and at end of treatment|Biomarker assessments, 1 hr post-study drug at cycles 1, 2, 4, 6 and End of Treatment|Pharmacokinetic assessments, 1 hr post-study drug, optional 3-5 hr post-study drug at cycles 1, 2, 3, 4, 5 and 6
The purpose of this study is to determine if adding ASA404 to docetaxel chemotherapy makes the cancer treatment more effective in patients with locally advanced or metastatic non-small cell lung cancer